Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some safety and adverse-reaction claims are partially supported (e.g., liver dysfunction, rhabdomyolysis, fatigue; and GI/diarrhea/nausea/myalgia as common discontinuation-related reactions; memory impairment as postmarketing). However, multiple claims overreach label detail (e.g., specifying “common” for headache, nausea, fatigue, diarrhea; attributing cognitive impairment to long-term use; linking type 2 diabetes, osteoporosis, and pancreatitis risk) and several are unsupported or not substantiated by the provided excerpts.
Category Scores
Accurate Statements
Lipitor can cause liver damage.
Label excerpt: “Statins… have been associated with biochemical abnormalities of liver function… Persistent elevations… It is recommended that liver function tests be performed…” and postmarketing includes “hepatic failure.”
Lipitor can cause rhabdomyolysis.
Label excerpt: “Rare cases of rhabdomyolysis with acute renal failure… have been reported…” and postmarketing includes “rhabdomyolysis.”
Some users have reported memory loss or confusion while taking Lipitor.
Label excerpt (postmarketing): “memory impairment” (and “depression” listed; confusion not explicitly provided in excerpt).
Lipitor has been linked to an increased risk of type 2 diabetes.
Common side effects of Lipitor include diarrhea.
Label excerpt: common adverse reactions leading to discontinuation include “diarrhea (0.5%)”; placebo-controlled adverse reactions include “diarrhea (6.8%).”
Common side effects of Lipitor include nausea.
Label excerpt: “nausea (0.4%)” among the five most common adverse reactions leading to discontinuation.
Common side effects of Lipitor include fatigue.
Label excerpt (postmarketing): includes “fatigue.” (No “common” frequency for fatigue provided in excerpts.)
Lipitor can cause muscle weakness.
Lipitor has been linked to an increased risk of pancreatitis.
Unsupported Statements
Lipitor is used to prevent heart disease.
Provided label supports cardiovascular disease risk reduction (myocardial infarction, stroke, revascularization, angina, CHF hospitalization) but does not explicitly state the shorter phrase “prevent heart disease” in the excerpts.
Common side effects of Lipitor include headache.
No headache is present in provided common adverse-reaction lists; “dizziness” is listed in postmarketing but not headache in the excerpts.
Lipitor liver damage from Lipitor is especially associated with high doses.
Label excerpts provided do not state that liver damage is especially associated with high doses.
Liver damage from Lipitor is especially associated with extended periods of use.
Label excerpts provided do not state that liver damage is especially associated with extended periods of use.
Liver damage associated with Lipitor is described as rare but serious.
The excerpts mention abnormalities and persistent transaminase elevations and contraindication for active liver disease; “rare but serious” phrasing for liver damage is not present in the provided excerpts.
Lipitor can cause cognitive impairment in some patients.
The excerpts mention “memory impairment” in postmarketing but do not explicitly support “cognitive impairment” as a general category.
Lipitor is linked to an increased risk of developing type 2 diabetes.
No diabetes/type 2 diabetes risk statement appears in the provided label excerpts.
Lipitor can cause muscle weakness.
The provided warnings mention myopathy/rhabdomyolysis, but the excerpt does not explicitly support “muscle weakness.”
Muscle weakness from Lipitor is especially associated with older adults.
No older-adult-specific association for muscle weakness/myopathy is provided in the excerpts.
Rhabdomyolysis associated with Lipitor is described as rare but serious.
The excerpt says “Rare cases of rhabdomyolysis…” but “serious” is not explicitly stated; however, severity is implied by “acute renal failure” language. (Classified as unsupported for the “rare but serious” combined characterization because “serious” is not explicitly provided.)
Pancreatitis described as a rare but serious side effect associated with Lipitor.
No pancreatitis statement appears in the provided label excerpts.
Long-term use of Lipitor can be associated with cognitive impairment.
The excerpts do not link cognitive effects to “long-term use.” Memory impairment is listed postmarketing without a duration link.
Long-term use of Lipitor can include memory loss.
Memory impairment is listed postmarketing, but the excerpt does not tie it to long-term use.
Long-term use of Lipitor can include confusion.
No “confusion” statement is provided in the excerpts (memory impairment is present). Also no long-term duration linkage provided.
Lipitor can cause long-term muscle damage.
No label excerpt provided supports “long-term muscle damage” wording.
Long-term muscle damage from Lipitor is especially associated with older adults.
No older-adult-specific association for long-term muscle damage is provided in the excerpts.
Long-term muscle damage is described as a common side effect of Lipitor in older adults.
The excerpts provide no “common” frequency for muscle-related adverse effects in older adults or any osteoporosis/age-specific long-term muscle damage statement.
Lipitor has been linked to an increased risk of osteoporosis.
No osteoporosis statement appears in the provided label excerpts.
Lipitor users are more likely to develop osteoporosis than those taking a placebo.
No osteoporosis comparison to placebo appears in the provided label excerpts.
Lipitor can cause muscle weakness.
Not explicitly supported by provided excerpts (myopathy/rhabdomyolysis discussed, but “muscle weakness” wording not present).
Lipitor can cause muscle weakness.
Provided warnings mention myopathy; however the specific claim uses “muscle weakness” and is not explicitly stated in excerpts.
Contradictions
Important Omissions
For indication claims, the label excerpt includes specific outcomes (reduce risk of MI, stroke, revascularization, angina, CHF hospitalization) and that therapy is adjunct to diet and multiple risk factor intervention; the AI claims were more general and did not reflect these specifics.
Importance:
Moderate
Boxed warnings are not evaluated because the provided excerpts do not include a boxed-warnings section; the AI claims include multiple safety assertions (e.g., cognitive impairment, diabetes, osteoporosis) without aligning to what the provided label excerpts actually emphasize.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety claims (type 2 diabetes risk, pancreatitis, osteoporosis; older-adult-specific associations; cognitive impairment/long-term linkage) are unsupported by the provided label excerpts, which could mislead risk interpretation. Supported claims about liver dysfunction and rhabdomyolysis are present.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims are not supported by the provided prescribing-information excerpts, especially those asserting diabetes risk, pancreatitis, osteoporosis, age- and duration-specific associations, and several “common side effect” labels (e.g., headache) not found in the excerpted adverse-reaction lists.
Suggested Improvement
Restrict claims to specific label-supported outcomes/adverse reactions from the provided excerpts (e.g., MI/stroke/revascularization/angina risk reduction; common discontinuation adverse reactions such as myalgia, diarrhea, nausea; postmarketing memory impairment; rare rhabdomyolysis). Remove unsupported risk links (diabetes, pancreatitis, osteoporosis) and avoid attributing frequency (“common”) or specificity (“older adults,” “long-term”) unless explicitly stated in the label excerpts.